吉西他滨联合奥沙利铂和地塞米松治疗复发或难治性非霍奇金淋巴瘤

Efficacy of GLD (gemcitabine,oxaliplatin,dexamethasone) regimen in recurrent and refractory non-Hodgkin' s lymphoma

目的:观察吉西他滨(Gem)、奥沙利铂(L-OHP)、地塞米松(DXM)组成的GLD联合化疗方案治疗21例复发或难治性非霍奇金淋巴瘤患者的近期疗效和毒副反应。方法:21例经正规治疗后复发或难治的非霍奇金淋巴瘤患者,采用GLD方案化疗:吉西他滨(Gem)1 000 mg/m^2,静脉滴注,第1、8天;奥沙利铂(L-OHP)85 mg/m^2,静脉滴注,第1、8天;地塞米松(DXM)40 mg/d,静脉滴注,第1～4天。以3～4周为1周期,每例患者至少连用2个周期。结果:21例患者中,15例获得缓解,占71.43%。其中完全缓解(CR)5例(23.81%),部分缓解(PR)10例(47.62%)。化疗毒副作用主要为骨髓抑制。其他有轻至中度的消化系统反应等。结论:吉西他滨联合奥沙利铂、地塞米松组成的GLD联合化疗方案对治疗复发性非霍奇金淋巴瘤患者有较好的近期疗效,毒副反应轻,能明显改善患者的症状,是一个值得进一步验证的补救性化疗方案。

Objeetive： To evaluate the effect and toxicity of gemcitabine combined with oxaliplatin and dexamethasone in the treatment of patients with relapsed or refractory non-Hodgkin＇s lymphoma. Methods： Twenty-one patients with confirmed relapsed or refractory non-Hodgkin＇s lymphoma were enrolled in this study. The chemotherapy regimen consisted of gemcitahine （1000 mg/m^2 , day 1 and 8） , oxaliplatin （85 mg/m^2 , day 1 and 8） and dexamethasone （40 mg/d, day 1-4） given every three to four weeks, at least 2 cycles of chemotherapy for each patient. Results： Of 21 patients, 15 patints showed response （71.43%） including 5 patients having complete response and 10 patients partial response. Drug related toxic effects were mild gastrointestinal reactions in most patients and mild hone marrow depression in few patients. Conclusion： The combination of gemcitabine, oxaliplatin and dexamethasone possesses better short term efficacy, acceptable toxicity, and obvious alleviation of symptoms related to the disease. This protocol is worthy to be warranted as salvage for relapsed or refractory non-Hodgkin＇s lymphoma.